ASH 2005

Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Owen O'Connor
Owen O’Connor

Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.


Click here for all the interviews from ASH 2005

Similar Interviews

  • Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma
  • Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine,

  • New Targets Bring Promise For Lung Cancer Therapy
  • Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising

  • Audio Journal of Hematologic Malignancy Special Edition 2005
  • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions, April

    Post a comment

    Subscribe to Audio Medica Podcast